Connect your AI

King Pharmaceuticals KG Sale of investments

Sale of investments at other companies

W.R. BerkleyWRB

——

Universal Insurance HoldingsUVE

——

Kearny FinancialKRNY

——

Other financials

Income statement

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

Operating cash flow-$15.1M-1,628%

Valuation

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

Net margin131.5%—

Returns & leverage

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's sale of investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is King Pharmaceuticals's sale of investments?: King Pharmaceuticals (KG) reported sale of investments of $38.12M in Q1 2026.